-+ 0.00%
-+ 0.00%
-+ 0.00%

HC Wainwright & Co. Maintains Buy on ORIC Pharmaceuticals, Lowers Price Target to $20

Benzinga·11/19/2026 11:27:32
Listen to the news
HC Wainwright & Co. analyst Robert Burns maintains ORIC Pharmaceuticals (NASDAQ:ORIC) with a Buy and lowers the price target from $27 to $20.